Read More

Allakos’ Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside

JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid immunoglobulin-like lectin) receptors on immune cells that are drivers of multiple diseases.

ALLK